Is Jubilant Pharmo technically bullish or bearish?

Technical Trend Shift and Current Price Action

As of 3 December 2025, Jubilant Pharmo's technical trend transitioned from mildly bullish to sideways, signalling a pause in directional momentum. The stock closed at ₹1,077.90, down from the previous close of ₹1,095.45, with intraday trading ranging between ₹1,071.40 and ₹1,098.20. This price action suggests a consolidation phase after recent volatility, with the stock currently trading below its 52-week high of ₹1,263.90 but comfortably above its 52-week low of ₹823.70.

Mixed Technical Indicators Paint a Complex Picture

Examining key technical indicators reveals a blend of bearish and mildly bullish signals. The Moving Average Convergence Divergence (MACD) on both weekly and monthly charts remains mildly bearish, indicating that momentum is not strongly in favour of upward price movement. Similarly, the Know Sure Thing (KST) oscillator aligns with this bearish tone on weekly and monthly timeframes.

Conversely, the daily moving averages suggest a mildly bullish bias, hinting at some short-term strength. Bollinger Bands present a split view: bearish on the weekly chart but mildly bullish on the monthly, reflecting potential volatility compression and a possible setup for a directional move. The Relative Strength Index (RSI) on weekly and monthly scales offers no clear signal, indicating neither overbought nor oversold conditions.

Additional indicators such as the Dow Theory and On-Balance Volume (OBV) lean mildly bearish on the weekly chart, with monthly readings showing no definitive trend. This combination underscores a market environment where selling pressure slightly outweighs buying interest, but without decisive momentum to drive a strong trend.

Performance Comparison with Sensex and Historical Returns

Jubilant Pharmo's recent price performance has lagged behind the broader market benchmark, the Sensex. Over the past week, the stock declined by 2.47%, compared to a modest 0.59% drop in the Sensex. The one-month return shows a sharper divergence, with Jubilant Pharmo falling 7.80% while the Sensex gained 1.34%. Year-to-date, the stock is down 2.54%, contrasting with the Sensex's 8.92% rise. Over the last year, the stock has declined 12.20%, whereas the Sensex has advanced 5.27%.

Despite recent underperformance, Jubilant Pharmo's longer-term returns remain impressive. Over three years, the stock has surged 184.44%, significantly outpacing the Sensex's 35.37% gain. However, over five and ten years, the stock's returns of 35.44% and 144.03% respectively trail the Sensex's 90.68% and 228.77%, reflecting periods of volatility and sector-specific challenges.

Sector Context and Industry Dynamics

Operating within the Pharmaceuticals & Biotechnology sector, Jubilant Pharmo faces a competitive and rapidly evolving landscape. The sector often experiences bouts of volatility driven by regulatory developments, research breakthroughs, and global health trends. Technical indicators for Jubilant Pharmo suggest the stock is currently digesting recent gains and sector headwinds, with investors awaiting clearer directional cues.

Given the sideways trend and mixed technical signals, market participants may adopt a cautious stance, monitoring for confirmation of either a breakout to the upside or a breakdown below key support levels. The stock's proximity to its 52-week high and low provides defined reference points for risk management.

Technical Outlook: Bullish or Bearish?

In aggregate, Jubilant Pharmo's technical profile is best characterised as neutral to mildly bearish in the medium term, with short-term indicators offering some mild bullish hints. The shift from a mildly bullish trend to sideways reflects a market indecision phase, where neither buyers nor sellers dominate decisively.

Key momentum indicators such as MACD and KST lean towards bearishness, while daily moving averages and monthly Bollinger Bands provide some counterbalance. The absence of strong RSI signals further emphasises the lack of clear directional conviction. This environment suggests that investors should exercise caution and look for confirmation signals before committing to a bullish stance.

Price action near the current levels will be critical. A sustained move above recent highs could reignite bullish momentum, whereas a breach below support levels may confirm a bearish continuation. Until such developments occur, the sideways trend is likely to persist.

Investor Considerations and Strategy

For investors considering Jubilant Pharmo, the current technical landscape advises a measured approach. The stock's recent underperformance relative to the Sensex and mixed technical signals suggest that aggressive bullish bets may be premature. Instead, monitoring volume patterns, momentum oscillators, and price behaviour around key moving averages will be essential to gauge the next directional move.

Long-term investors may find value in Jubilant Pharmo's historical outperformance over three years, but should remain mindful of the recent sideways consolidation and sector volatility. Diversification and comparison with alternative opportunities within the Pharmaceuticals & Biotechnology space could enhance portfolio resilience.

Conclusion

Jubilant Pharmo currently exhibits a technical stance that is neither strongly bullish nor overtly bearish, but rather sideways with a mild bearish tilt on several momentum indicators. This suggests a period of consolidation and indecision, with investors advised to await clearer signals before positioning for a sustained trend. The stock's mixed technical readings, combined with recent relative underperformance, underscore the importance of cautious analysis and disciplined risk management in navigating this phase.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →